Symbols

CNTX

Context Therapeutics·NASDAQ

--(--)

Signals Analysis

Bullish signal 2

Bearish signal 1

Stock Price Surged Significantly

Consensus Rating "Strong Buy"

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About CNTX

Context Therapeutics Inc.

A biopharmaceutical company focused on developing hormone therapies for cancer treatment

Industry

Pharmaceutical

Established Date

Listing Date

10/20/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.contexttherapeutics.com

Security Type

Common stock

Office address

2001 Market Street, Suite 3915, Unit #15, Philadelphia, Pennsylvania 19103

Business

Introduction

Context Therapeutics Inc., was incorporated in Delaware in April 2015. The company is a clinical-stage biopharmaceutical company advancing T-cell-bridging bispecific antibodies for solid tumors. Its R&D pipeline includes CTIM-76 targeting CLDN 6, CT-95 targeting mesothelin, and CT-202 targeting Nectin-4, and these drug candidates are in or planned for Phase 1 clinical trials.

Company Financials

EPS

CNTX has released its 2025 Q4 earnings. EPS was reported at -0.14, versus the expected -0.1, missing expectations. The chart below visualizes how CNTX has performed over recent quarters, highlighting trends in earnings surprises.